HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TDOC
Teladoc Health, Inc.
TDOC lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TDOC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Healthy |
TDOC's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TDOC PE Valuation
TDOC has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TDOC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TDOC's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TDOC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.86 | +$0.41 |
| Q2 2026 | -$0.99 | +$0.19 |
| Q1 2026 | -$0.97 | +$4.94 |
| Q4 2025 | -$1.14 | +$4.73 |
| Q3 2025 | -$1.27 | +$4.50 |
| Q2 2025 | -$1.18 | +$4.75 |
| Q1 2025 | -$5.91 | -$4.50 |
| Q4 2024 | -$5.87 | -$4.53 |
TDOC has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TDOC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TDOC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $605.1M | -3.4% |
| Q2 2026 | $606.9M | -4% |
| Q1 2026 | $613.8M | -2.5% |
| Q4 2025 | $642.3M | +0.3% |
| Q3 2025 | $626.4M | -2.2% |
| Q2 2025 | $631.9M | -1.6% |
| Q1 2025 | $629.4M | -2.6% |
| Q4 2024 | $640.5M | -3% |
TDOC's revenue grew through 2022 and has held roughly level since: $605M last quarter, down 3.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.6% | +3.6 points |
| Q2 2026 | -6.1% | +2.5 points |
| Q1 2026 | -10% | +9.1 points |
| Q4 2025 | -5.6% | +1.9 points |
| Q3 2025 | -8.3% | -1.4 points |
| Q2 2025 | -8.6% | +122 points |
| Q1 2025 | -19% | -5.7 points |
| Q4 2024 | -7.5% | -2.2 points |
TDOC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TDOC on cash flow, with more consistent year-over-year improvement.
TDOC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $105.2M | +8.5% |
| Q2 2026 | $63.7M | -29% |
| Q1 2026 | $7.9M | -40% |
| Q4 2025 | $85.1M | +6.7% |
| Q3 2025 | $97M | -11% |
| Q2 2025 | $90.2M | +3.9% |
| Q1 2025 | $13.2M | +70% |
| Q4 2024 | $79.8M | -38% |
TDOC generated $262M in free cash flow over the past year, down 6.5% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TDOC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TDOC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +850K shares |
| 1 year | +2.8% | +4.9M shares |
| 3 years | +10% | +16.8M shares |
| 5 years | +14% | +22.4M shares |
| Available history | +151% | +109M shares |
TDOC has 182M diluted shares, up 2.8% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TDOC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.1x | Net Cash |
| Q2 2026 | -4.3x | Net Cash |
| Q1 2026 | -4.6x | Net Cash |
| Q4 2025 | -7.7x | Net Cash |
| Q3 2025 | -8.7x | Net Cash |
| Q2 2025 | -7.4x | Net Cash |
TDOC has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TDOC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.1 | Neutral |
| Stochastic | 75.8 | Neutral |
TDOC's weekly RSI is 63 (neutral) and its Stochastic is 76 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TDOC PE vs Healthcare Sector
TDOC has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TDOC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.92 | 26% above |
| 20 week MA | $7.22 | 20% above |
| 50 week MA | $6.68 | 30% above |
| 100 week MA | $7.51 | 16% above |
| 200 week MA | $12.6 | 31% below |
TDOC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TDOC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $83.4 | $208.0 | +149% |
| 2021 | $208.0 | $95.1 | -54% |
| 2022 | $95.1 | $23.5 | -75% |
| 2023 | $23.5 | $21.6 | -8.4% |
| 2024 | $21.6 | $9.45 | -56% |
| 2025 | $9.45 | $7.12 | -25% |
| 2026 YTD | $7.12 | $8.69 | +22% |
TDOC has the edge over HIMS on returns for 2026, with the stronger performance.